{"id":4106,"date":"2017-12-25T11:41:21","date_gmt":"2017-12-25T10:41:21","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/pionier-der-immunonkologie-fuer-bis-zu-464-millionen-euro-verkauft\/"},"modified":"2020-06-29T14:46:28","modified_gmt":"2020-06-29T12:46:28","slug":"immuno-oncology-pioneer-sold-for-up-to-464-million-euros","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/","title":{"rendered":"Immuno-oncology pioneer sold for up to 464 Million Euros"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row el_class=&#8221;gco-magazine-container&#8221;][vc_column el_class=&#8221;bildspalte&#8221;][vc_row_inner][vc_column_inner offset=&#8221;vc_col-lg-12 vc_col-md-12&#8243;][vc_column_text el_class=&#8221;gco-magazine&#8211;title&#8221;]<\/p>\n<h1>I<span style=\"font-size: xx-large;\">mmuno-oncology pioneer sold for up to 464 Million Euros<br \/>\n<\/span><\/h1>\n<p>[\/vc_column_text][vc_column_text el_class=&#8221;gco-magazine-lead&#8221;]MSD to acquire Rigontec GmbH<br \/>\n[\/vc_column_text][vc_column_text el_class=&#8221;gco-magazine&#8211;post-date&#8221;]December 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=&#8221;gco-magazine-container&#8211;copy&#8221;][vc_column_inner][vc_column_text]MSD (Merck, Sharp &amp; Dohme Corp.) and Rigontec announced on September 6, 2017 that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Under the terms of the agreement, MSD, through a subsidiary, will make an upfront cash payment of 115 million Euros to Rigontec\u2019s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, MSD may make additional contingent payments of up to 349 million Euros. The transaction is subject to certain closing conditions.<br \/>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=&#8221;gco-magazine&#8211;quote&#8221;][vc_column_inner][vc_single_image image=&#8221;4102&#8243; img_size=&#8221;155&#215;155&#8243; alignment=&#8221;center&#8221; style=&#8221;vc_box_circle_2&#8243;][vc_column_text el_class=&#8221;gco-magazine&#8211;picture-discription-blank&#8221;]Dr. Christian Schetter,<br \/>\nCEO, Rigontec GmbH<br \/>\n[\/vc_column_text][vc_column_text el_class=&#8221;gco-magazine-copyright-blank&#8221;]<\/p>\n<p style=\"text-align: center;\">\u00a9 Rigontec<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=&#8221;gco-magazine-container&#8211;copy&#8221;][vc_column_inner][vc_column_text]\u201cRigontec\u2019s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our current pipeline,\u201d said Dr. Eric Rubin, vice president of early-stage development, clinical oncology, MSD Research Laboratories. \u201cWe are eager to build upon Rigontec\u2019s science as we continue our efforts in bringing forward meaningful advances for patients with cancer.\u201d<br \/>\n\u201cMSD is a true pioneer in the immuno-oncology space and we are thrilled that our technology will benefit from their experience and leadership position,\u201d said Dr. Christian Schetter, CEO of Rigontec. \u201cWe are confident that our programs will be in the best hands and that the team at MSD will continue the work we established with our scientific founders and brought into the clinic within three years since our foundation as a company.\u201d[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p><span class=\"gco-utils-excerpt\" data-debug-trim-excerpt=\"346\"><span class=\"gco-utils-excerpt__part-xs\">MSD (Merck, Sharp &#038; Dohme Corp.) and Rigontec announced on September 6, 2017 that MSD will<\/span><span class=\"gco-utils-excerpt__part-xl\"> acquire Rigontec. Rigontec is a pioneer in accessing the retinoic<\/span><\/span><\/p>\n","protected":false},"author":1,"featured_media":4104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[286],"tags":[],"class_list":["post-4106","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-izb-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Immuno-oncology pioneer sold for up to 464 Million Euros - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuno-oncology pioneer sold for up to 464 Million Euros\" \/>\n<meta property=\"og:description\" content=\"MSD (Merck, Sharp &amp; Dohme Corp.) and Rigontec announced on September 6, 2017 that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-25T10:41:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-29T12:46:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"255\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"p534396\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"p534396\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/\"},\"author\":{\"name\":\"p534396\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/12499d818c4e3f59388b94103f0a527e\"},\"headline\":\"Immuno-oncology pioneer sold for up to 464 Million Euros\",\"datePublished\":\"2017-12-25T10:41:21+00:00\",\"dateModified\":\"2020-06-29T12:46:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg\",\"articleSection\":[\"IZB News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/\",\"name\":\"Immuno-oncology pioneer sold for up to 464 Million Euros - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg\",\"datePublished\":\"2017-12-25T10:41:21+00:00\",\"dateModified\":\"2020-06-29T12:46:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg\",\"width\":400,\"height\":255,\"caption\":\"Portrait-Dr.-Christian-Schetter\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZB Biotech News\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/izb-biotech-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IZB News\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/izb-biotech-news\\\/izb-news\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Immuno-oncology pioneer sold for up to 464 Million Euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/12499d818c4e3f59388b94103f0a527e\",\"name\":\"p534396\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immuno-oncology pioneer sold for up to 464 Million Euros - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/","og_locale":"en_US","og_type":"article","og_title":"Immuno-oncology pioneer sold for up to 464 Million Euros","og_description":"MSD (Merck, Sharp & Dohme Corp.) and Rigontec announced on September 6, 2017 that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.","og_url":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_published_time":"2017-12-25T10:41:21+00:00","article_modified_time":"2020-06-29T12:46:28+00:00","og_image":[{"width":400,"height":255,"url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg","type":"image\/jpeg"}],"author":"p534396","twitter_card":"summary_large_image","twitter_misc":{"Written by":"p534396","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#article","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/"},"author":{"name":"p534396","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/12499d818c4e3f59388b94103f0a527e"},"headline":"Immuno-oncology pioneer sold for up to 464 Million Euros","datePublished":"2017-12-25T10:41:21+00:00","dateModified":"2020-06-29T12:46:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg","articleSection":["IZB News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/","url":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/","name":"Immuno-oncology pioneer sold for up to 464 Million Euros - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#primaryimage"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg","datePublished":"2017-12-25T10:41:21+00:00","dateModified":"2020-06-29T12:46:28+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#primaryimage","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_IZB-News_Schetter_20173_beitragsbild_version-quer.jpg","width":400,"height":255,"caption":"Portrait-Dr.-Christian-Schetter"},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/immuno-oncology-pioneer-sold-for-up-to-464-million-euros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZB Biotech News","item":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/"},{"@type":"ListItem","position":3,"name":"IZB News","item":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/izb-news\/"},{"@type":"ListItem","position":4,"name":"Immuno-oncology pioneer sold for up to 464 Million Euros"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/12499d818c4e3f59388b94103f0a527e","name":"p534396"}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/comments?post=4106"}],"version-history":[{"count":12,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4106\/revisions"}],"predecessor-version":[{"id":11555,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4106\/revisions\/11555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media\/4104"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=4106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/categories?post=4106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/tags?post=4106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}